Jiangsu Tianhe Pharmaceutical
China Updated 9 July 2026
Jiangsu Tianhe Pharmaceutical is a contract manufacturer based in China. It holds 2 active US drug master files. Its most recent recorded inspection, by US FDA, closed on 3 August 2018 as VAI.
1
registered plants
1 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| China, China | 3010939885 |
What they file, and where
| Molecule | Regulators | Docs |
| Sulfadimethoxine | US FDA | 2 |
Also appears on these molecule pages
Comparing suppliers?
Choose your molecules and target markets. Jiangsu Tianhe Pharmaceutical comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 3 August 2018.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability